Aristo Bio-Tech & Lifescience Ltd

Aristo Bio-Tech has demonstrated consistent growth in net sales and profitability over the past five years, with net sales increasing from INR 165.76 crore in March 2022 to INR 318.09 crore in March 2025, despite rising raw material costs impacting profit margins. The company has also improved its operating profit and cash flow, indicating a strengthening financial position.

As of 28-Oct, Aristo Bio-Tech & Lifescience Ltd's stock price is 125.05, down 3.81%, and has underperformed its sector by 4.71%. The stock has seen a significant drop in delivery volume and negative returns over the past week, month, and year, contrasting with the positive performance of the broader market.

As of 30-Sep, Aristo Bio-Tech & Lifescience Ltd's stock price is at 132.70, up 5.15%, but delivery volume has decreased by 68.75%, indicating reduced investor participation. Despite a positive month with a 10.03% gain, the decline in delivery volume may pose challenges for future price movements.

As of 29-Sep, Aristo Bio-Tech & Lifescience Ltd's stock price is at 126.20, down 8.42%, and has underperformed its sector by 8.19%. The stock is facing declining investor interest and has dropped 5.11% year-to-date, contrasting with the Sensex's 4.19% gain.

As of 24-Sep, Aristo Bio-Tech & Lifescience Ltd is priced at 137.80, with no change today. Despite a 24.03% increase over the past month, declining investor participation and mixed short-term momentum may raise concerns about future price movements.

As of September 23, 2025, Aristo Bio-Tech is considered very expensive and overvalued with a PE Ratio of 23.11, an EV to EBITDA of 12.36, and a PEG Ratio of 5.63, despite a strong one-year return of 35.1%, indicating that its current price of 137.80 is not justified compared to its peers.

As of 23-Sep, Aristo Bio-Tech & Lifescience Ltd's stock price is at 137.80, unchanged today, but it has outperformed its sector by 1.2%. Despite a strong year-to-date return of 3.61% and a one-year return of 35.10%, a significant drop in delivery volume may indicate declining investor interest.

As of September 22, 2025, Aristo Bio-Tech is considered overvalued with a valuation grade of "expensive," reflected in its PE Ratio of 23.11 and a PEG Ratio of 5.63, despite outperforming the Sensex with a 26.42% return over the past year.

As of 22-Sep, Aristo Bio-Tech & Lifescience Ltd is priced at 137.80, with no change today. The stock has shown strong monthly performance but recent delivery volume has dropped significantly, indicating decreased investor interest and mixed short-term momentum signals.

As of September 19, 2025, Aristo Bio-Tech is considered very expensive and overvalued with a PE ratio of 23.14, despite outperforming the Sensex with a 1-year return of 28.79%, while its peers UPL and Bayer CropScience have even higher PE ratios of 38.81 and 40.59, respectively.

As of September 19, 2025, Aristo Bio-Tech is considered very expensive and overvalued with a PE Ratio of 23.14, an EV to EBITDA of 12.37, and a PEG Ratio of 5.64, especially when compared to peers like UPL and BASF India, despite a recent 1-year return of 28.79%.

As of September 19, 2025, Aristo Bio-Tech is considered very expensive with a PE ratio of 23.14 and a current price of 137.80, indicating it is overvalued compared to its peers and growth expectations, despite a 28.79% return over the past year.

As of 19-Sep, Aristo Bio-Tech & Lifescience Ltd's stock price is slightly down at 137.80, despite a strong monthly return of 19.31%. The recent decline in delivery volume and underperformance against its sector may indicate waning investor interest.

As of 18-Sep, Aristo Bio-Tech & Lifescience Ltd is priced at 138.00, down 0.72%. Despite this decline, the stock has performed well recently, with a 6.15% increase over the past week and a 25.45% rise over the past month, outperforming the benchmark Sensex.

As of September 17, 2025, Aristo Bio-Tech is considered expensive and overvalued with a PE Ratio of 23.31, despite outperforming the Sensex with a 30.95% return, as it trades at a premium compared to its earnings growth potential and is more expensive than some peers like Sharda Cropchem.

As of 17-Sep, Aristo Bio-Tech & Lifescience Ltd is priced at 139.00 with no change, reflecting a 0.00% movement. The stock has shown strong short-term gains, increasing by 6.92% over the past week and 20.87% over the past month, but has lagged behind the Sensex year-to-date.

As of September 16, 2025, Aristo Bio-Tech is considered very expensive and overvalued, with a PE Ratio of 23.31, despite outperforming the Sensex with a 1-year return of 30.95%.

As of September 15, 2025, Aristo Bio-Tech is considered overvalued with a valuation grade of expensive, reflected in its PE ratio of 22.80 and a PEG ratio of 5.56, despite a recent stock return of 33.33% that outperformed the Sensex.

As of 15-Sep, Aristo Bio-Tech & Lifescience Ltd is experiencing a price increase to 140.00, reflecting a rise of 2.94% and strong performance compared to the Sensex. The stock has outperformed the benchmark significantly over the past week and month, indicating robust investor confidence.